S. Gail Eckhardt

Statistics

Publications

Citations

2.8K

H-Index

Active since

1994

Affiliations

The University of Texas at San Antonio Health Science Center(Current)

University of Colorado Denver

Brooke Army Medical Center

University of Colorado Anschutz Medical Campus

International Drug Development

S. Gail Eckhardt is an author at The University of Texas at San Antonio Health Science Center specializing in pharmacology, medicine, and cancer pharmacology.

Publications per year

1994–2020

Publications

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 440 citations

Life Sciences, Oncology, Pharmacology +17

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Mace L. Rothenberg, John R. Eckardt, John G. Kuhn et al. · Journal of Clinical Oncology · 1996 · 352 citations

Medicine, Oncology, Pharmacology +13

MERTK receptor tyrosine kinase is a therapeutic target in melanoma

Jennifer Schlegel, Maria J. Sambade, Susan Sather et al. · Journal of Clinical Investigation · 2013 · 144 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies

Lisa A. Hammond, John R. Eckardt, Sharyn D. Baker et al. · Journal of Clinical Oncology · 1999 · 134 citations

Medicine, Oncology, Pharmacology +17

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Amita Patnaik, Eric K. Rowinsky, Miguel A. Villalona et al. · PubMed · 2002 · 124 citations

Medicine, Oncology, Pharmacology +11

1–5 of 38